Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)

China · Delayed Price · Currency is CNY

3.100

+0.020 (0.65%)

Oct 28, 2026, 12:24 PM CST

Market Cap	9.31B -18.0%
Revenue (ttm)	4.33B -22.3%
Net Income	17.95M
EPS	0.01
Shares Out	3.00B
PE Ratio	317.79
Forward PE	22.00
Dividend	0.01 (0.32%)
Ex-Dividend Date	Jul 15, 2026

Volume	15,527,423
Open	3.050
Previous Close	3.080
Day's Range	3.050 - 3.110
52-Week Range	2.820 - 3.990
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHE:300026

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and sale of various pharmaceutical products in China. The company offers traditional Chinese medicine formula granules; finished drugs, including xuebijing injections, low molecular weight heparin calcium injections, moxifloxacin hydrochloride sodium chloride injections, enoxaparin sodium injections, nadronexacin calcium injections, fasudil hydrochloride injections, ketorheic acid tromethamine injections, ibanoxetine sodium injections, Qingfei Sanjie pill... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1996

Employees 4,852

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300026

Full Company Profile

Financial Performance

In 2025, SHE:300026's revenue was 4.94 billion, a decrease of -14.55% compared to the previous year's 5.78 billion. Earnings were 18.50 million, a decrease of -13.85%.

Financial Statements